Integrating data from randomized controlled trials and observational studies to predict the response to pregabalin in patients with painful diabetic peripheral neuropathy

Table 4 ARMAX model predictive capability for pain and responder status in the validation dataset

Clusters^a	Observed vs. estimated, P value
	Pain level for responders		Responder status achieved
	At 50% threshold	At 30% threshold	At 50% threshold	At 30% threshold
1	0.52	0.31	0.50	0.20
2	0.78	0.16	0.65	0.11
3	0.29	0.22	0.26	0.14
4	0.71	0.32	0.83	0.28
5	0.66	0.42	0.73	0.25
6	0.76	0.30	0.79	0.25

Abbreviations: ARMAX autoregressive moving average model, RCT randomized controlled trial
^aObservational study dataset of patients not matched with RCT patients

ISSN: 1471-2288